FdaApplication
NDA 209394
Identifiers
- fda_app_no: NDA209394
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2017-08-03 |
Revenue by product
MAVYRET
| Period | Revenue |
|---|---|
| Q2 2026 | $295.0M* |
| Q1 2026 | $351.0M* |
| Q4 2025 | $324.0M* |
| Q3 2025 | $312.0M* |
| Q2 2025 | $375.0M* |
| Q1 2025 | $306.0M* |
| Q4 2024 | $291.0M* |
| Q3 2024 | $302.0M* |
| Q2 2024 | $369.0M* |
| Q1 2024 | $349.0M* |
| Q4 2023 | $309.0M* |
| Q3 2023 | $370.0M* |
| Q2 2023 | $387.0M* |
| Q1 2023 | $364.0M* |
| Q4 2022 | $380.0M* |
| Q3 2022 | $383.0M* |
| Q2 2022 | $398.0M* |
| Q1 2022 | $380.0M* |
| Q4 2021 | $427.0M* |
| Q3 2021 | $426.0M* |
| Q2 2021 | $442.0M* |
| Q1 2021 | $415.0M* |
| Q4 2020 | $481.0M* |
| Q3 2020 | $414.0M* |
| Q2 2020 | $376.0M* |
| Q1 2020 | $559.0M* |
| Q4 2019 | $628.0M* |
| Q3 2019 | $695.0M* |
| Q2 2019 | $780.0M* |
| Q1 2019 | $790.0M* |
| Q4 2018 | $819.0M* |
| Q3 2018 | $839.0M* |
| Q2 2018 | $932.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| MAVYRET | GLECAPREVIR; PIBRENTASVIR | 100MG;40MG | TABLET;ORAL |
1 product